U.S. markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.07-0.04 (-0.44%)
At close: 04:00PM EST
9.07 0.00 (0.00%)
After hours: 04:10PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Flag (Bearish)

Flag (Bearish)

Previous Close9.11
Bid9.08 x 1000
Ask9.10 x 800
Day's Range9.06 - 9.68
52 Week Range9.06 - 37.07
Avg. Volume895,729
Market Cap385.675M
Beta (5Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)-3.28
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GTHX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • G1 Therapeutics, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Simply Wall St.

    Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

    RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January. G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January

  • GlobeNewswire

    G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), and an aggregate of 50,200 shares of G1’s common stock to seven employees under the previously-announced G1 Therapeutics, Inc.